Patency-Coronary Trial (PATENCY)
Recruitment status was: Recruiting
|Complications Due to Coronary Artery Bypass Graft Graft Failure||Procedure: On-pump CABG Procedure: Off-pump CABG|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
|Official Title:||PATency assessmENt of Grafts by Computerized tomographY in CORONARY Patients: the PATENCY-CORONARY Trial|
- CABG Patency index [ Time Frame: 12 months ]CABG patency index (i.e. the percentage of patent [non-occluded] distal anastomoses out of the total number of distal anastomoses for all patients) at 1 year after CABG surgery by experienced surgeons.
- Graft lesion severity [ Time Frame: 12 months ]Graft lesion severity on a 3-point scale at 1 year (mimicking the FitzGibbon grading ABO).
- Patients with at least one occluded graft [ Time Frame: 12 months ]Percentage of patients with at least one occluded bypass graft at 1 year.
- Grafts compromised and clinical outcomes [ Time Frame: 12 months and 5 years ]Correlation between CTA findings (compromised grafts) with clinical primary outcomes of CORONARY trial (Myocardial infarct, Stroke, death), at one and five-year of follow-up post-CABG.
|Study Start Date:||August 2011|
|Estimated Study Completion Date:||September 2015|
|Estimated Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
|Experimental: On-pump CABG||
Procedure: On-pump CABG
Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
|Experimental: Off-pump CABG||
Procedure: Off-pump CABG
CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
Other Name: Beating heart
Background: As Coronary Artery Bypass Grafting (CABG) aims to restore adequate blood supply to the ischemic heart, the success of the operation should depend mainly on the patency of the bypass grafts. Graft failure has consequences similar to those of native coronary artery disease: recurrent angina, myocardial infarct (MI), additional revascularization procedures, and premature death. CABG is generally performed using cardiopulmonary bypass (CPB) with cardioplegic arrest allowing the surgeon to complete the delicate coronary anastomoses on a still heart in a bloodless field. Off-pump CABG surgery using specially designed heart stabilizer systems has been proposed as a less invasive approach to CABG avoiding the CPB circuit itself. The benefits of off-pump CABG compared with conventional on-pump CABG are still intensively debated. Multislice spiral computed tomography angiography (CTA) represents a non-invasive method as compared to conventional coronary angiography allowing a comprehensive and objective imaging of bypass grafts and native coronaries with elevated diagnostic accuracy.
Rationale: CORONARY trial (NCT00463294) is a large, international, prospective, CIHR-funded, randomized controlled trial assessing both the short and long-term clinical outcomes of 4,700 patients undergoing on-pump or off-pump CABG. However, angiographic evaluation of coronary graft patency was not intended in CORONARY.
Objectives: PATENCY-CORONARY is a new prospective trial of a consecutive subset of 1,200 CORONARY patients reaching their one-year follow-up who will undergo graft patency assessment using CTA and 3D reconstructions. This trial will determine whether off-pump compared to on-pump CABG surgery is associated with lower CABG patency when performed by experienced surgeons and if there is an association between graft failure assessed by CTA, and the occurrence of CORONARY primary outcomes (composite of death, angina, MI, stroke, renal failure and new coronary revascularization [CABG or PCI]).
Primary outcome: CABG patency index (i.e. the percentage of patent [non-occluded] distal anastomoses out of the total number of distal anastomoses for all patients) at 1 year after CABG surgery by experienced surgeons; Secondary outcomes: 1) graft lesion severity on a 3-point scale at 1 year (mimicking the FitzGibbon grading ABO); and 2) percentage of patients with at least one occluded bypass graft at 1 year; Tertiary outcome: correlation between CTA findings (compromised grafts) with CORONARY primary outcomes(composite of death, angina, MI, stroke, renal failure and new coronary revascularization [CABG or PCI]), at one and five-year of follow-up post-CABG.
Methods: All CORONARY patients reaching their one-year follow-up will be included consecutively in the PATENCY-CORONARY trial until the target of 1,200 CTA is reached and reasons for exclusion will be noted prospectively to prevent selection bias. Amount of contrast agent used, radiation dose and potential morbidities during this imaging procedure will be recorded. Each CTA examination will be assessed by two experienced and blinded radiologists and each graft will be classified according to conduit type and portions: body of the graft, anastomoses and the distal native coronary bed. In addition of PATENCY-CORONARY outcome analyses, patients undergoing CTA will be compared to excluded patients (no CTA) and the overall cohort of patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01414049
|Contact: Nicolas Noiseux, MDfirstname.lastname@example.org|
|Contact: Louis Mathieu Stevens, MDemail@example.com|
|Libin Cardiovascular Institute of Alberta||Not yet recruiting|
|Calgary, Alberta, Canada, T2N 2T9|
|Contact: Teresa Keiser, MD firstname.lastname@example.org|
|Sub-Investigator: Teresa Kieser, MD|
|Population Health Research Institute||Not yet recruiting|
|Hamilton, Ontario, Canada, L8L2X2|
|Contact: Andre Lamy, MD 905-527-4322 ext 40635 email@example.com|
|Contact: Jessica Vincent 905-527-4322 ext 40635 firstname.lastname@example.org|
|Principal Investigator: André Lamy, MD|
|Centre Hospitalier University de Montreal||Recruiting|
|Montreal, Quebec, Canada, H2W1T8|
|Contact: Nicolas Noiseux, MD 514-890-8131 email@example.com|
|Contact: Louis Mathieu Stevens, MD 514-890-8131 firstname.lastname@example.org|
|Sub-Investigator: Louis Mathieu Stevens, MD|
|Sub-Investigator: Carl Chartrand-Lefebvre, MD|
|Principal Investigator: Gilles Soulez, MD|
|Principal Investigator: Nicolas Noiseux, MD|
|Sub-Investigator: Samer Mansour, MD|
|Principal Investigator:||Nicolas Noiseux, MD||CRCHUM, Montreal University|